Literature DB >> 18607560

Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy?

D N Sang1, P A D'Amore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18607560     DOI： 10.1007/s00125-008-1078-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  34 in total

1.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

2.  Pathophysiological consequences of VEGF-induced vascular permeability.

Authors:  Sara M Weis; David A Cheresh
Journal:  Nature       Date:  2005-09-22       Impact factor: 49.962

3.  Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

4.  Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways.

Authors:  Ulkan Kilic; Ertugrul Kilic; Anne Järve; Zeyun Guo; Annett Spudich; Katja Bieber; Uxue Barzena; Claudio L Bassetti; Hugo H Marti; Dirk M Hermann
Journal:  J Neurosci       Date:  2006-11-29       Impact factor: 6.167

5.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Authors:  Kazuaki Nishijima; Yin-Shan Ng; Lichun Zhong; John Bradley; William Schubert; Nobuo Jo; Jo Akita; Steven J Samuelsson; Gregory S Robinson; Anthony P Adamis; David T Shima
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.

Authors:  J Fernando Arevalo; Jans Fromow-Guerra; Hugo Quiroz-Mercado; Juan G Sanchez; Lihteh Wu; Mauricio Maia; Maria H Berrocal; Adriana Solis-Vivanco; Michel E Farah
Journal:  Ophthalmology       Date:  2007-04       Impact factor: 12.079

8.  Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.

Authors:  Swaantje Peters; Peter Heiduschka; Sylvie Julien; Focke Ziemssen; Heike Fietz; Karl Ulrich Bartz-Schmidt; Ulrich Schraermeyer
Journal:  Am J Ophthalmol       Date:  2007-04-23       Impact factor: 5.258

9.  Detection of diabetic macular edema. Ophthalmoscopy versus photography--Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group.

Authors:  J Kinyoun; F Barton; M Fisher; L Hubbard; L Aiello; F Ferris
Journal:  Ophthalmology       Date:  1989-06       Impact factor: 12.079

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245
View more
  18 in total

1.  Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization.

Authors:  Joshua M Barnett; Sandra Suarez; Gary W McCollum; John S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-26       Impact factor: 4.799

2.  Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis.

Authors:  Jonathan D Lam; Daniel J Oh; Lindsay L Wong; Dhanesh Amarnani; Cindy Park-Windhol; Angie V Sanchez; Jonathan Cardona-Velez; Declan McGuone; Anat O Stemmer-Rachamimov; Dean Eliott; Diane R Bielenberg; Tave van Zyl; Lishuang Shen; Xiaowu Gai; Patricia A D'Amore; Leo A Kim; Joseph F Arboleda-Velasquez
Journal:  Diabetes       Date:  2017-04-11       Impact factor: 9.461

3.  Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-β/δ.

Authors:  Sandra Suarez; Gary W McCollum; Colin A Bretz; Rong Yang; Megan E Capozzi; John S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-18       Impact factor: 4.799

Review 4.  Current approaches to the management of diabetic retinopathy and diabetic macular oedema.

Authors:  Francesco Boscia
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

5.  A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy.

Authors:  Sampathkumar Rangasamy; Ramprasad Srinivasan; Joann Maestas; Paul G McGuire; Arup Das
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

6.  [Diabetic retinopathy and maculopathy].

Authors:  H-P Hammes
Journal:  Internist (Berl)       Date:  2011-05       Impact factor: 0.743

Review 7.  Advances in the medical treatment of diabetic retinopathy.

Authors:  Rafael Simó; Cristina Hernández
Journal:  Diabetes Care       Date:  2009-08       Impact factor: 17.152

8.  Blood coagulation parameters after intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration.

Authors:  Hasan Altinkaynak; Meltem Ece Kars; Piraye Zeynep Kurkcuoglu; Nagihan Ugurlu
Journal:  Int Ophthalmol       Date:  2017-10-12       Impact factor: 2.031

9.  Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema.

Authors:  Moataz F Elsawy
Journal:  Clin Ophthalmol       Date:  2012-12-11

10.  Diabetic retinopathy and inflammation: novel therapeutic targets.

Authors:  Sampathkumar Rangasamy; Paul G McGuire; Arup Das
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.